Recent Updates of Lipoprotein(a) and Cardiovascular Disease
- Author:
Taili LIU
1
;
Won-Sik YOON
;
Sang-Rok LEE
Author Information
- Publication Type:Review Article
- From:Chonnam Medical Journal 2021;57(1):36-43
- CountryRepublic of Korea
- Language:English
- Abstract: In recent years, epidemiological studies, genome-wide association studies, and Mendelian randomization studies have shown a strong association between increased levels of lipoproteins and increased risks of coronary heart disease and cardiovascular disease (CVD). Although lipoprotein(a) [Lp(a)] was an independent risk factor for ASCVD, the latest international clinical guidelines do not recommend direct reduction of plasma Lp(a) concentrations. The main reason was that there is no effective clinical medicine that directly lowers plasma Lp(a) concentrations. However, recent clinical trials have shown that proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9) and second-generation antisense oligonucleotides can effectively reduce plasma Lp(a) levels.This review will present the structure, pathogenicity, prognostic evidences, and recent advances in therapeutic drugs for Lp(a).
